|
CDKN2A
|
CDKN2A presence of homozygous deletion n (%)
|
CDKN2A absence of homozygous deletion n (%)
|
p
|
|---|
|
Age
| |
62
|
62,6
|
NS
|
|
Gender
|
Women
|
6 (12)
|
44 (88)
|
0,157
|
| |
Men
|
2 (4)
|
46 (96)
| |
|
Histology
|
ADC
|
7 (10)
|
61 (90)
|
0,483
|
| |
LCC
|
0 (0)
|
6 (100)
| |
| |
SCC
|
1 (4)
|
23 (96)
| |
|
Tobacco
|
Never-smoker
|
5 (20)
|
20 (80)
|
0,012
|
| |
Smoker
|
3 (4)
|
70 (96)
| |
| |
Mutated
|
5 (33)
|
10 (67)
| |
|
EGFR
|
Non-mutated
|
3 (4)
|
80 (96)
|
0,002
|
| |
Mutated
|
1 (5)
|
19 (95)
| |
|
KRAS
|
Non-mutated
|
7 (9)
|
71 (91)
|
0,563
|
| |
Mutated
|
1 (14)
|
6 (86)
| |
|
STK11
|
Non-mutated
|
7 (8)
|
84 (92)
|
0,46
|
| |
Mutated
|
3 (7)
|
40 (93)
| |
|
TP53
|
Non-mutated
|
5 (9)
|
50 (91)
|
0,704
|
|
AKT-mTOR activation*
|
Yes
|
7 (29)
|
17 (71)
|
<0,001
|
| |
No
|
1 (1)
|
73 (99)
| |
|
CCND1
|
Amplification n (%)
|
No amplification n (%)
|
P
|
|
Age
| |
61,8
|
63
|
NS
|
|
Gender
|
Women
|
5 (10)
|
45 (90)
|
0,331
|
| |
Men
|
8 (17)
|
40 (83)
| |
|
Histology
|
ADC
|
6 (9)
|
62 (91)
|
0,079
|
| |
LCC
|
2 (33)
|
4 (67)
| |
| |
SCC
|
5 (21)
|
19 (71)
| |
|
Tobacco
|
Never-smoker
|
0
|
25 (100)
|
0,023
|
| |
Smoker
|
13 (18)
|
60 (82)
| |
|
EGFR
|
Mutated
|
1 (7)
|
14 (93)
|
0,331
|
| |
Non-mutated
|
12 (14)
|
71 (86)
| |
|
KRAS
|
Mutated
|
2 (10)
|
18 (90)
|
0,629
|
| |
Non-mutated
|
11 (14)
|
67 (86)
| |
|
STK11
|
Mutated
|
1 (1)
|
6 (99)
|
0,934
|
| |
Non-mutated
|
12 (13)
|
79 (87)
| |
|
TP53
|
Mutated
|
9 (21)
|
34 (79)
|
0,048
|
| |
Non-mutated
|
4 (7)
|
51 (83)
| |
|
AKT-mTOR activation*
|
Yes
|
2 (8)
|
22 (92)
|
0,412
|
| |
No
|
11 (15)
|
63 (85)
| |
|
CCNE1
|
Amplification n (%)
|
No-amplification n (%)
|
P
|
|
Age
| |
67
|
62,5
|
NS
|
|
Gender
|
Women
|
2 (4)
|
47 (96)
|
0,371
|
| |
Men
|
4 (8)
|
45 (92)
| |
|
Histology
|
ADC
|
2 (3)
|
66 (97)
|
0,099
|
| |
LCC
|
1 (1)
|
5 (99)
| |
| |
SCC
|
3 (13)
|
21 (87)
| |
|
Tobacco
|
Never-smoker
|
1 (1)
|
24 (99)
|
0,518
|
| |
Smoker
|
5 (17)
|
68 (83)
| |
|
EGFR
|
Mutated
|
1 (1)
|
14 (99)
|
0,924
|
| |
Non-mutated
|
5 (7)
|
78 (93)
| |
|
KRAS
|
Mutated
|
1 (1)
|
19 (99)
|
0,814
|
| |
Non-mutated
|
5 (6)
|
73 (94)
| |
|
STK11
|
Mutated
|
0
|
7 (100)
|
0,483
|
| |
Non-mutated
|
6 (7)
|
85 (93)
| |
|
TP53
|
Mutated
|
6 (15)
|
37 (85)
|
0,006
|
| |
Non-mutated
|
0
|
55 (100)
| |
|
AKT-mTOR activation*
|
Yes
|
2 (8)
|
22 (82)
|
0,603
|
| |
No
|
4 (5)
|
70 (85)
| |
- In this work we called PI3K-AKT-mTOR activated tumors, tumors with either EGFR, PIK3CA, ERBB2 or STK11 mutation*.
